Benny Sorensen

Benny Sorensen, MD, PhD, joined as CEO of Hemab Therapeutics from Codiak Biosciences where he served as Senior Vice President, Head of Clinical Development and Strategic Projects. During his tenure, he was involved with building the company and leading non-clinical, clinical, and regulatory affairs and advancing the first-ever engineered exosome therapeutics from idea into clinical proof of concept. Dr. Sorensen remains member of the Scientific Advisory Board at Codiak. Before Codiak, he was Senior Director of Clinical Research at Alnylam Pharmaceuticals, where he led development of fitusiran and other hematology products. Previously, he was a Global Medical Director at Baxter Healthcare Corporation advancing pivotal development of Adynovate® and Vonvendi®. He has more than 15 years of experience in clinical and translational research and management. Prior to industry, he was the Director of the Haemostasis Research Unit and Honorary Lecturer at Guy’s and St. Thomas’ Hospital & King’s College London School of Medicine, where he led basic translational research and advancement of several clinical trials across Phases I, II, and III. Dr. Sorensen earned his MD and PhD in Medicine degrees from Aarhus University, Denmark, and has published extensively in hematology translational and clinical research.